Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo
- PMID: 34648046
- DOI: 10.1007/s00234-021-02828-2
Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo
Abstract
Purpose: We planned this prospective study to evaluate PSMA expression in recurrent high-grade gliomas (rHGG), including anaplastic astrocytoma and glioblastoma using Glu-NH-CO-NH-Lys-(Ahx)-[Ga-68 (HBED-CC)]- (Ga-68 PSMA) positron emission tomography (PET), with its theranostic potential in mind.
Methods: This was a prospective study enrolling patients with clinical and MRI evidence of rHGG on follow-up. Three treated cases of HGG with RN on MRI were also included as negative controls. Abnormal tracer accumulation in the brain parenchyma, more than the contralateral hemisphere was interpreted as positive study. For semiquantitative analysis, a 3D spherical region of interest (ROI) was drawn around the site of the abnormal Ga-68 PSMA uptake, and the ratio of SUVmax of tumor (T) to SUVmax of the contralateral corresponding area (TBR) was calculated. Each patients' PSMA brain PET was fused to the corresponding MRI and reviewed for concordance.
Results: Thirty patients were included in the study, a total of 49 lesions were detected on MRI, and fused PET/MR images showed increased Ga-68 PSMA uptake in all these lesions. Multifocal lesions were better appreciated on fused PET-MR images, and concordance between MRI and PET was 100 % for patient and lesion-wise detection. Recurrent glioma lesions showed SUVmax and SUVmean values (median and IQR) 6.0 (4.4-8.2) and 3.3 (2.8-3.7), respectively. Lesions labeled as radiation necrosis on MRI did not show tracer accumulation.
Conclusion: Ga-68 PSMA has potential utility for evaluating recurrence in HGG and its potential for theranostics would encourage its use in the evaluation of these patients.
Keywords: Ga-68 PSMA; PET; PET/MRI fusion; Recurrent high-grade glioma.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Stupp R, Hegi ME, Mason WP, an den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7 - DOI - PubMed
-
- Easaw JC, Mason WP, Perry J, Laperrière N, Eisenstat DD, Del Maestro R et al (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol Tor Ont 18:e126–e136. https://doi.org/10.3747/co.v18i3.755 - DOI
-
- Nelson SJ (1999) Imaging of brain tumors after therapy. Neuroimaging Clin N Am 9:801–819 - PubMed
-
- Zhang H, Ma L, Wang Q, Zheng X, Wu C, Xu B-N (2014) Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis. Eur J Radiol 83:2181–2189. https://doi.org/10.1016/j.ejrad.2014.09.018 - DOI - PubMed
-
- Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MM et al (2012) Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med 37:158–163. https://doi.org/10.1097/RLU.0b013e318238f51a - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous